SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Olympus Corporation OCPNY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Olympus Corporation (OCPNY) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $18.00. It has a SharesGrow Score of 77/100, indicating a strong investment profile with 4 out of 7 criteria passed.

Financials: revenue is $868.9B, +3.7%/yr average growth. Net income is $116.0B, growing at +419%/yr. Net profit margin is 13.3% (healthy). Gross margin is 65.8% (+1.6 pp trend).

Balance sheet: total debt is $386.1B against $510.2B equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.85 (strong liquidity). Debt-to-assets is 28.4%. Total assets: $1.4T.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 66/100 (Partial), Future ?/100 (Fail), Income 55/100 (Partial).

OCPNY SharesGrow Score Overview

80/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 73/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 66/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OCPNY

OCPNY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

OCPNY: +3.7%/yr revenue is, +419%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

OCPNY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet OCPNY: Debt-to-Equity (D/E) ratio 0.76 (moderate), Current ratio is 1.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

OCPNY: Gross margin is 65.8% (+1.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 66/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

OCPNY: Net profit margin is 13.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range16.8-74.99

Volume465

Avg Volume (30D)493.73K

Beta (1Y)0.00

Dividend Yield$1.2212

Share Statistics

EPS (TTM)90.35

Shares Outstanding$1.28B

IPO Date1993-06-01

Employees31,557

CEOYasuo Takeuchi

Financial Highlights & Ratios

Revenue (TTM)$868.87B

Gross Profit$571.7B

EBITDA$219.64B

Net Income$115.97B

Operating Income$155.03B

Total Cash$312.84B

Total Debt$386.13B

Net Debt$83.56B

Total Assets$1.36T

Price / Earnings (P/E)0.2

Analyst Forecast

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINUS68163W1099

Price Chart

OCPNY

Olympus Corporation ↗ · Other OTC

Healthcare • Medical - Instruments & Supplies

16.80 52WK RANGE 74.99

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message